On May 12, U.S. Food and Drug Administration (FDA) Commissioner Dr. Marty Makary resigned from his position after 13 months.
As reported by The New York Times, he faced mounting pressure and criticism, ultimately leaving over the Trump administration’s plans to authorize fruit-flavored e-cigarettes and vapes.
Makary is a surgical oncologist, professor, researcher, author and medical commentator who was appointed FDA Commissioner on April 1, 2025. Effective immediately, Kyle Diamantas, JD, deputy commissioner for human foods at FDA, took over as acting commissioner.
The Natural Products Association (NPA), American Herbal Products Association (AHPA) and Consumer Healthcare Products Association (CHPA) responded to Makary’s departure from FDA.
“We congratulate Mr. Diamantas on being named acting commissioner of FDA. He has shown a tremendous track record on the food and dietary supplement side of the house at FDA, and we anticipate that will continue under his leadership,” said Daniel Fabricant, PhD, president and CEO of NPA.
“Guided by our commitment to science, safety, and transparency in the herbal product and dietary supplement industries, AHPA recognizes the critical role the FDA Commissioner plays in overseeing public health,” said AHPA President and CEO Graham Rigby. “While leadership transitions are a matter of administrative policy, AHPA is committed to maintaining a constructive dialogue with FDA to ensure that the interests of our members and the health of the consumers they serve are represented. AHPA has furthered strong relationships with a number of appointed and unappointed agency leaders under this administration, including Kyle Diamantas. We look forward to our continued collaboration with him and his team at FDA to advance a regulatory environment that supports both innovation and consumer safety.”
“CHPA appreciates Dr. Makary’s public service at the FDA during a consequential time for health care. Throughout his tenure, Commissioner Makary consistently recognized and publicly emphasized the important role self-care products play in expanding access, lowering costs, and helping Americans more easily manage their health,” said Scott Melville, president and CEO of CHPA. “The unprecedented pace of leadership transition across the FDA this past year underscores the need for regulatory stability, predictability, and continuity. It’s essential to protect public health, maintain consumer confidence, and enable industry innovation. CHPA looks forward to continuing to work collaboratively with Acting Commissioner Diamantas and the broader FDA leadership team to help translate access and affordability priorities into policies and actions that expand Americans’ ability to obtain safe, effective, and reliable self-care products.”
For more information, visit www.fda.gov.
